Chief Executive Officer and Director
Robert Berman has served as our Chief Executive Officer since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of ITUS Corporation, a Nasdaq listed company that is developing a liquid biopsy technology for early cancer detection. Prior to ITUS, Mr. Berman was the CEO of VIZ Technologies, a start-up company which developed a beverage dispensing cap, and he was the founder of IP Dispute Resolution Corporation, a company focused on intellectual property licensing. From 2000 to March 2007 Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, which became the preeminent, publicly traded company for licensing and enforcing patented technologies. He started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northwestern University School of Law, where he is an adjunct faculty member.
Marc Glickman, M.D.
Senior Vice President and Chief Medical Officer
Marc H. Glickman, M.D. has served as our Senior Vice President and Chief Medical Officer since May 2016 and served as member of our board of directors from July 2016 to August 2017. In 1981, Dr. Glickman started a vascular practice in Norfolk, Virginia. He established the first Vein Center in Virginia and also created a dialysis access center. He was employed by Sentara Health Care as director of Vascular Services until he retired in 2014. Dr. Glickman is a board certified vascular surgeon. Dr. Glickman received his Doctor of Medicine from Case Western Reserve, in Cleveland, Ohio and completed his residency at the University of Washington, Seattle. He is board certified in Vascular Surgery and was the past president of the Vascular Society of the Americas. He has served on the advisory boards of Possis Medical, Cohesion Technologies, Thoratec, GraftCath, Inc., TVA medical, Austin, Texas.
Director of Research and Development
Brian Roselauf brings 16 years of engineering product development experience and a track record of bringing concepts to commercialization within large publicly traded companies as well as startups. He also has an extensive background in developing implantable prosthetic devices through his professional experiences with Edwards Lifesciences, Arbor Surgical Technologies, Endologix, CardiAQ, and HighLife Medical. Notably, Brian worked with Covidien Neurovascular which was purchased by Medtronic for $43 billion, CardiAQ, which was later purchased by Edwards Lifesciences for $400 million, and HighLife Medical, which recently received $36 million in Series B funding. Brian’s breadth technical skills in a multitude of engineering disciplines, expertise in project management, and leadership experiences will drive technology development at HJLI. Brian has an Executive MBA from UCLA’s Anderson School of Management, an M.S. is Mechanical Engineering from California State Polytechnic University Pomona, and a B.S. in Bioengineering from the University of California San Diego. Brian is also a health and wellness advocate and a 10-time IRONMAN finisher.